Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor

Apoptosis

Volumn 10, Issue 6, 2005, Pages 1411-1418

  Ray, S ^a   Bucur, O ^a,b   Almasan, A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Apo2l TRAIL; Apoptosis; Bcl 2; Bcl xL; BH3 mimetic; Prostate cancer

Indexed keywords

BCL 2 HOMOLOGY 3 DOMAIN PROTEIN INHIBITOR 2'; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BH3 PROTEIN; CASPASE 3; CASPASE 8; CASPASE INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL STRAIN LNCAP; DIMERIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; SENSITIZATION;

EID: 30944438284     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-005-2490-y     Document Type: Article

References (40)

1. Almasan A, Ashkenazi A. Apo2L/TRAIL: Apoposis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003; 14: 337-348.
2. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-219.
3. Lazebnik YA, Kaufmann SH, Desnoyers S, et al. Cleavage of poly(ADP-nbose) polymerase by a proteinase with properties like ICE. Nature (Lond) 1994; 371: 346-347.
4. Degterev A, Lugovskoy A, Cardone M, et al. Identification of the small-molecule inhibitors of interactions between the BH3 domain and Bcl-xL. Nature Cell Biol 2001; 3: 173-182.
5. Green RD, Kroemer G. The Pathophysiology of mitochondrial cell death. Science 2004; 305: 626-629.
6. Zou H, Li Y, Liu X, Wang X. An APAF-1-cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999; 274: 11549-11556.
7. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1998; 1: 949-957.
8. Boehning D, Petterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nature Cell Biol 2003; 5:1051-1061.
9. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
10. Hao JH, Yu M, Liu FT, Newland AC, Jia L. Bcl-2 Inhibitors sensitize Tumor Necrosis Factor-Related Apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res 2004; 64:3607-3616.
11. Feng WY, Liu FT, Patwari Y Agrawal SG, Newland AC, Jia AL. BH3-domain mimetic compound BH3I-2′ induced rapid damage to inner mitochondrial membrane prior to cytochrome c release from mitochondria. Br J Haematol 2003; 121: 332-340.
12. Shankar S, Srivastava RK. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: Mechanisms and clinical implications. Drug Resist Update 2004; 7: 139-156.
13. Gong B, Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 2000; 60: 5754-5760.
14. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2: 1273-1284.
15. Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol 2003; 66: 1537-1545.
16. Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: Role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004; 314: 186-191.
17. Cuello M, Coats AO, Darko I, et al. N-(4-Hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial- dependent amplification loop in ovarian cancer cell lines. Cell Death Differ 2004; 11: 527-541.
18. Sun SY, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000; 19: 4513-4522.
19. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000; 60: 7149-7155.
20. Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000; 20: 205-212.
21. Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999; 59: 6153-6158.
22. Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734-741.
23. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 2003; 63: 5390-5400.
24. Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate 2004; 60: 115-128.
25. Shankar S, Chen X, Thakkar H, Firnin J, Srivastava RK. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int J Oncol 2004; 24: 1133-1140.
26. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003; 63: 4713-4723.
27. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54: 2577-2581.
28. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
29. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Investig 1999; 104: 155-162.
30. Chen Q, Gong B, Almasan A. Distinct stages of cytochrome c release from mitochondria: Evidence for a feedback amplification loop linking caspase activation to mitochondrial dysfunction in genotoxic stress induced apoptosis. Cell Death Differ 2000; 7: 227-233.
31. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000; 60: 847-853.
32. Palayoor ST, Bump EA, Teicher BA, Coleman CN. Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin. Radiat Res 1997; 148: 105-114.
33. Chou TC, Talalay P. Quantitative analysis of dose-response relationships: The combined effect of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
34. Mazumder S, Gong B, Chen Q, Drazba JA, Buchsbaum JC, Almasan A. Proteolytic cleavage of cyclin E leads to inactivation of associated kinase activity and amplification of apoptosis in hematopoietic cells. Mol Cell Biol 2002; 22: 2398-2409.
35. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol 1998; 28: 143-152.
36. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997; 137: 221-229.
37. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490.
38. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
39. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-1163.
40. LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor-Induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281.